RecruitingPhase 1NCT06963281
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
A Phase 1, Multicenter, Open-label Study of IBI3020 Treatment in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Enrollment
285 participants
Start Date
Apr 29, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria9
- Participants must satisfy all of the following criteria to be enrolled into the study:
- Participants have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol;
- Male or female participants ≥ 18 years old. For Part 1, age ≥ 18 years and ≤ 75 years;
- Histologically or cytologically confirmed unresectable, locally advanced or metastatic solid tumors which have received available standard therapies and have disease progression, or unacceptable toxic effects, or contraindications;
- At least 1 measurable lesion as defined per RECIST v1.1 within 28 days prior to the first dose of IBI3020;
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1;
- Minimum life expectancy of 12 weeks;
- Adequate bone marrow and organ function confirmed at screening period;
- Participants, both male and female, who are not of childbearing potential or who agree to use at least 1 highly effective method of contraception during the study.
Exclusion Criteria16
- Participants who meet any of the following criteria will be disqualified from entering the study:
- Previous treatment with CEACAM5-targeted therapy;
- Prior anti-cancer therapy within the wash-out period;
- Received live vaccines within 4 weeks or cancer vaccine within 3 months;
- Potent cytochrome P450 3A4 (CYP3A4) inhibitors within 2 weeks or 5 half-lives;
- Has adverse reactions resulting from previous anti-tumor therapies, which have not resolved to Grade 0 or 1 toxicity according to NCI CTCAE v5.0;
- Known allergies, hypersensitivity, or intolerance to IBI3020 or its excipients;
- Undergone major surgery within 4 weeks, or who have severe unhealed wounds;
- Known symptomatic central nervous system (CNS) metastases;
- Uncontrolled diseases or conditions;
- History of pneumonitis requiring corticosteroids therapy, or history of clinically significant lung diseases;
- History of thromboembolic event within 6 months;
- Under neurological, psychiatric or social condition;
- Women who are pregnant, have positive results in pregnancy test or are lactating;
- Not eligible to participate in this study at the discretion of the investigator;
- Participating in any other interventional clinical research.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGIBI3020
Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06963281
Related Trials
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT0688528121 locations
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073212 locations
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
NCT070438941 location
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
NCT069267511 location
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
NCT067614171 location